Trial Search Results

A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 2)

The purpose of this study is to look at the effects, good or bad, of MPDL3280A (a monoclonal antibody) on patients with bladder cancer.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Hoffmann-La Roche

Stanford Investigator(s):


  • Drug: Atezolizumab


Phase 2


Inclusion Criteria:

   - Histologically or cytologically documented locally advanced or metastatic transitional
   cell carcinoma of the urothelium (including renal pelvis, ureters, urinary bladder,

   - Representative tumor specimens as specified by the protocol

   - Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

   - Life expectancy greater than or equal to (>=) 12 weeks

   - Measurable disease, as defined by RECIST v1.1

   - Adequate hematologic and end organ function

Cohort 2-Specific Inclusion Criteria

   - Disease progression during or following treatment with at least one
   platinum-containing regimen (e.g., gemcitabine and cisplatin [GC], methotrexate,
   vinblastine, doxorubicin, and cisplatin [MVAC], CarboGem, etc.) for inoperable locally
   advanced or metastatic urothelial carcinoma or disease recurrence.

   - A regimen was defined as participants receiving at least two cycles of a
   platinum-containing regimen. Participants who had received one cycle of a
   platinum-containing regimen but discontinued due to Grade 4 hematologic toxicity or
   Grade 3 or 4 non-hematologic toxicity could also be eligible.

   - Participants who received prior adjuvant/neoadjuvant chemotherapy and progressed
   within 12 months of treatment with a platinum-containing adjuvant/neoadjuvant regimen
   were considered as second-line participants.

Exclusion Criteria:

   - Any approved anti-cancer therapy within 3 weeks prior to initiation of study treatment

   - Treatment with any other investigational agent or participation in another clinical
   trial with therapeutic intent within 28 days prior to enrollment

   - Active or untreated central nervous system (CNS) metastases as determined by computed
   tomography (CT) or magnetic resonance imaging (MRI) evaluation during screening and
   prior radiographic assessments

   - Leptomeningeal disease

   - Uncontrolled tumor-related pain

   - Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent
   drainage procedures (once monthly or more frequently)

   - Uncontrolled hypercalcemia (greater than [>] 1.5 millimoles per liter [mmol/L] ionized
   calcium or Ca > 12 milligrams per deciliter [mg/dL] or corrected serum calcium > upper
   limits of normal [ULN]) or symptomatic hypercalcemia requiring continued use of
   bisphosphonate therapy or denosumab

   - Malignancies other than urothelial bladder cancer within 5 years prior to Cycle 1, Day
   1, with the exception of those with a negligible risk of metastasis or death treated
   with expected curative outcome or incidental prostate cancer

   - Pregnant and lactating women

   - History of autoimmune disease

   - History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced
   pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening
   chest CT scan

   - Serum albumin less than (<) 2.5 grams per deciliter (g/dL)

   - Positive test for human immunodeficiency virus (HIV) and/or active hepatitis B or
   hepatitis C or tuberculosis

   - Severe infections within 4 weeks prior to Cycle 1, Day 1

   - Significant cardiovascular disease

   - Major surgical procedure other than for diagnosis within 28 days prior to Cycle 1, Day

   - Prior allogeneic stem cell or solid organ transplant

   - Administration of a live, attenuated vaccine within 4 weeks before Cycle 1, Day 1

   - Any other diseases, metabolic dysfunction, physical examination finding, or clinical
   laboratory finding giving reasonable suspicion of a disease or condition that
   contraindicates the use of an investigational drug or that may affect the
   interpretation of the results or render the patient at high risk from treatment

   - Prior treatment with CD137 agonists or immune checkpoint blockade therapies, including
   anti-cytotoxic T lymphocyte-associated antigen 4 (anti-CTLA-4), anti-programmed
   death-1 receptor (anti-PD-1), and anti-programmed death-ligand 1 (anti-PD-L1)
   therapeutic antibodies

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Not Recruiting